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1. Introduction1
Renal fibrosis is not only in the development of a variety of 
chronic kidney disease (CKD) is an important pathologi-
cal change, but also through this pathway will lead to ad-
vanced kidney disease (ESRD). It is considered to be an ir-
reversible disease, which will result in irreversible damage 
to renal function, which is mainly manifested in the pro-
gressive development of renal tubular interstitial fibrosis 
and tubular atrophy, which determines the prognosis of re-
nal disease. For kidney disease patients, the dialysis treat-
ment and renal transplantation that they have undergo will 
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consume a lot of financial and material resources which 
has brought considerably burden to these family, medical 
institutions and the community. The treatment method 
that can directly prevent and reverse renal fibrosis has not 
yet been found. The treatment to delay the development 
of chronic kidney disease to kidney failure still has a long 
way to go. Literature studies have shown that A & B has a 
strong anti-renal fibrosis effect, which can alleviate the re-
nal tubular epithelial cell damage and inhibit renal intersti-
tial fibrosis [1−3]. In this paper, 40 male SD SPF rats were 
selected to observe the effects of A, B and molecular medi-
cine on the renal fibrosis in rats.
2. Materials and methods
2.1. General information
A total of 40 male SD SPF rats were selected, where the 
rats aged is 45−60 d and body weight of rats is 210−250 g 
and were raised in the SPF animal room which free access 
to food and water with adaptive feeding 3 d after entering 
the experiment. The 40 rats were divided into 4 groups: 
control group, A group, B group and A + B group, 10 rats 
in each group. The four groups of rats on the age, body 
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weight, feeding methods and other general information are 
not statistical significance (p > 0.05), with comparable.
2.2. Method
The purity of Salvianolic Acid A and B were more than 
98%. After entering the experiment, all the rats with uni-
lateral ureteral obstruction (UUO) was used to establish a 
model of renal interstitial fibrosis. After two days of mod-
eling, salvianolic acid A, B, A + B groups was given three 
intervention for 2 weeks. After the end of treatment col-
lected 24 h urine, abdominal aortic blood taken, picking 
the right renal tissue, and opened along the longitudinal 
axis, with 4% paraformaldehyde fixed and were usually 
placed in liquid nitrogen preservation. The HE score and 
Masson score and PDGF-c/PDGFR-α expression of were 
compared among the groups.
2.3. Statistical analysis
All the statistical analysis of the data was statistically ana-
lyzed by SPSS 12.0 software. Continuous data were ex-
pressed as mean ± standard deviation ( x  ± s). Student t 
test analyses for comparison between groups, all were done 
as 2-sided tests, when p < 0.05 was considered statistically 
significant.
3. Results
3.1. Pathological score of four groups of rats
The pathological score of kidney tissue was significantly 
higher than that in the control group (p < 0.05), the HE 
and Masson scores in the model group were significantly 
higher than those in the control group (UUO < 1). Com-
pared with the model group, the HE and Masson scores in 
the treatment group were significantly decreased (p < 0.05), 
the B and HE scores of the rats in the treatment group 
were significantly lower than those in the Masson group (p 
< 0.05), and the difference was not statistically significant 
(p > 0.05) in the A + B group. It is showed that the compat-
ibility of A, B and its molecular medicine can improve the 
renal pathological damage and reduce the deposition of 
collagen.
3.2. Expression of PDGF-C and PDGFR-α protein in re-
nal tissue of rats
The results showed that: compared with control group, 
PDGF-C mRNA and PDGFR-α mRNA expression in 
model group were significantly higher than that in model 
group (p < 0.05), and A + B and PDGFR-α mRNA expres-
sion were significantly lower than that in A group (p < 0.05), 
and the effect was better than that in A group (p < 0.05), 
and the difference was statistically significant (p < 0.05). 
The expression of PDGF-C/PDGFR-α, A and B in the kid-
ney tissue of rats were treated with, and the effect of A + B 
group was better than that of A and B group.
4. Discussion
In our country, there is a deep research in the field of clini-
cal treatment of kidney disease. It is proved that the ef-
fect of A and B has a strong anti-renal fibrosis, which can 
relieve the damage of renal tubular epithelial cells and 
inhibit renal interstitial fibrosis. Research by Li Qun et al. 
[4] on salvianolic acid B in improving mechanism of aris-
tolochic acid nephropathy study showed that salvianolic 
acid B has powerful antioxidant function which can inhibit 
thrombosis. In the field of clinical treatment of renal fibro-
sis has remarkable curative effect. Foreign scholars Chen 
YT [5] considered that the Platelet-Derived Growth Factor 
(PDGF) and PDGFR-α enhanced the migration of fibro-
blasts in the kidney, and increased the activity of PDGF 
and PDGFR-α in the process of fibrosis leading to severe 
collagen deposition. In this study, the collagen deposition 
was significantly decreased in the A and B treated rats. 
Among salvianolic acid A, B, A + B of the three groups, 
Table 1. Pathological score of renal tissue in four groups ( ~x  ± s).
Group Cases Dose/mg·Kg-1 HE Score Masson Score
Control group 10 - 2.96 ± 0.08 2.93 ± 0.04
salvianolic acid A 10 12.5 1.80 ± 0.07 1.76 ± 0.08
salvianolic acid B 10 12.5 1.16 ± 0.06 1.28 ± 0.05
salvianolic acid A+B 10 6.25 + 6.25 1.02 ± 0.12 0.90 ± 0.05
p Value - - < 0.05 < 0.05
Table 2. Expression of PDGF-C and PDGFR- protein in renal tissue of rats ( ~x  ± s).
Group Cases Dose/mg·Kg-1 PDGF-C mRNA PDGFR-α mRNA
Control group 10 - 1.43 ± 0.16 11.22 ± 0.71
salvianolic acid A 10 12.5 1.07 ± 0.17 8.61 ± 0.37
salvianolic acid B 10 12.5 0.75 ± 0.07 7.36 ± 1.21
salvianolic acid A + B 10 6.25+6.25 0.62 ± 0.08 5.21 ± 1.72
p Value - - < 0.05 < 0.05
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salvianolic acid A + B group on HE score and Masson 
score was significantly lower than that of salvianolic acid 
A group (p < 0.05). It was suggested that the compatibility 
of A, B and A + B could effectively improve the renal tissue 
function and alleviate renal interstitial fibrosis. In com-
parison with the control group, the PDGF-c of A, B, A + 
B and PDGFR-α were significantly decreased (p < 0.05) in 
the control group. Salvianolic acid A, B, A + B of the three 
groups showed that salvianolic acid A + B dose group rat 
renal tissue relative expression of PDGF-c protein was sig-
nificantly lower than that of salvianolic acid A group and 
salvianolic acid B group. Thus, the intervention of A, B and 
PDGF-c/PDGFR-α in the process of renal fibrosis was sig-
nificant, and the effect of PDGF-c/PDGFR-α in the A + B 
group was significantly stronger than that of A, B.
Salvionalic B and CTGF group can significantly improve 
rat kidney tissue pathological changes and its effect is bet-
ter than that of A group. The group can significantly reduce 
the collagen deposition in rats. The effect is better than 
that of A. The effect of Par-3 was significantly decreased in 
rats. The component compatibility group can significantly 
reduce the relative expression of PDGF-c mRNA renal 
tissue in rat where the effect is better than in salvianolic 
acids in group A. In addition, the component compatibil-
ity group can significantly reduce the rat kidney PDGFR 
alpha relative mRNA and PDGF-c protein expression. The 
effect was better than in salvionalic acids A and group B. 
There was no significant difference in the improvement 
of renal function and renal tubular function in rats with 
the combination of molecular and molecular medicine. 
A, B and its molecular agents can improve renal function, 
renal tubular function and renal pathology in UUO rats. 
The mechanism may be related to the expression of Par-3 
and PDGF-c/PDGFR-α in renal tissues of UUO rats. The 
mechanism may be related to the expression of PDGF-c 
and PDGFR-α in renal tissue.
In summary, the compatibility of A, B and PDGF-c can 
significantly improve the pathological changes of renal tis-
sue fibrosis in rats. The expression of A, B and PDGFR can 
significantly reduce the renal function, renal tubular func-
tion and renal pathology.
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